Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving trastuzumab together with ixabepilone and
carboplatin works in treating patients with HER2/neu-positive metastatic breast cancer.
Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or
deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy, such as ixabepilone and carboplatin, work in different ways to stop tumor cells
from dividing so they stop growing or die. Combining trastuzumab with ixabepilone and
carboplatin may kill more tumor cells.